Fueled by recent clinical success, cancer immunotherapy using antibodies that specifically target CTLA-4 and the PD-1/PD-L1 axis to block immune inhibitory pathways is emerging as a promising future for cancer therapy. This evidence concerns the gene CD274 and cancer.